|
Q1 FY2023
As of Jun 30, 2022
|
Q4 FY2022
As of Mar 31, 2022
|
Q3 FY2022
As of Dec 31, 2021
|
Q2 FY2022
As of Sep 30, 2021
|
Q1 FY2022
As of Jun 30, 2021
|
Q4 FY2021
As of Mar 31, 2021
|
Q3 FY2021
As of Dec 31, 2020
|
Q2 FY2021
As of Sep 30, 2020
|
Q1 FY2021
As of Jun 30, 2020
|
Q4 FY2020
As of Mar 31, 2020
|
Q3 FY2020
As of Dec 31, 2019
|
Q2 FY2020
As of Sep 30, 2019
|
Q1 FY2020
As of Jun 30, 2019
|
Q4 FY2019
As of Mar 31, 2019
|
Q3 FY2019
As of Dec 31, 2018
|
Q2 FY2019
As of Sep 30, 2018
|
Q1 FY2019
As of Jun 30, 2018
|
Q4 FY2018
As of Mar 31, 2018
|
Q3 FY2018
As of Dec 31, 2017
|
Q2 FY2018
As of Sep 30, 2017
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Current Assets | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Marketable securities | ||||||||||||||||||||
| Prepaid clinical costs | ||||||||||||||||||||
| Prepaid expenses and other current assets | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Property and equipment, net | ||||||||||||||||||||
| Prepaid clinical costs, net of current portion | ||||||||||||||||||||
| Operating lease right-of-use asset | ||||||||||||||||||||
| Marketable securities | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Liabilities and Stockholders' Equity | ||||||||||||||||||||
| Current liabilities | ||||||||||||||||||||
| Accounts payable and other current liabilities (including $0 and $153,000 of related party accounts payable, respectively) | ||||||||||||||||||||
| Severance payable | ||||||||||||||||||||
| Accrued bonuses | ||||||||||||||||||||
| Insurance note payable | ||||||||||||||||||||
| Operating lease liability | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Long-term liabilities | ||||||||||||||||||||
| Severance payable, net of current portion | ||||||||||||||||||||
| Operating lease liability, net of current portion | ||||||||||||||||||||
| Warrant liability | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Stockholders' equity | ||||||||||||||||||||
| Common stock, $0.0001 par value, 300,000,000 shares authorized, 172,206,894 issued and outstanding at June 30, 2022, 300,000,000 authorized, 172,206,894 issued and outstanding at March 31, 2022 | ||||||||||||||||||||
| Additional paid in capital | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Total stockholders' equity | ||||||||||||||||||||
| Total liabilities and stockholders' equity | ||||||||||||||||||||
Loading...
